Full video transcriptClick to expand
Auto-generated transcript of @user6760823034903's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Let's say there were no such thing as GLP ones.
- 0:02Let's say we were just looking at that.
- 0:03You go, well, that is starvation.
- 0:05That's an eating disorder.
- 0:06If she was not in a concentration camp.
- 0:09But now we have a drug that causes that.
- 0:12Let me throw to one other thing here,
- 0:13because we've talked a lot about O'Zempic
- 0:15and the GLP ones on the show.
- 0:17And obviously Drew, you've helped us understand
- 0:20a little more what's going on there.
- 0:22Olivia Wilde, honestly, I'm not hugely familiar
- 0:25with her work, but she's an actress.
- 0:26And a video came out of her on a red carpet.
- 0:30And the drastic change in her book.
- 0:33Take a look at this.
- 0:34When I read this script, it was already set in San Francisco.
- 0:37And she, the Jones and Wilma Cormack,
- 0:39had made that decision.
- 0:40And I was so immediately intrigued,
- 0:42because I do love the city.
- 0:44And I feel that it's so telling when a script sets
- 0:49a very specific location.
- 0:50You can tell how what that's supposed to mean
- 0:53and what it means about these characters.
- 0:54And as you see, when you'll see the film, hopefully,
- 0:58it really does make sense that this particular group
- 1:00is from here.
- 1:02And.
- 1:03Okay, so you don't even really need to listen
- 1:04to what she's talking about there.
- 1:06You look at that picture of her.
- 1:08She's, by any estimation, I think you'd say
- 1:11she's objectively a beautiful woman.
- 1:13She's beautiful.
- 1:14Yeah.
- 1:15You know, she had a certain structure to her face
- 1:17or something that maybe she wasn't happy with.
- 1:19Like, like, it was a little wide or something.
- 1:21Like, that just sounds crazy to even say.
- 1:23But she was absolutely beautiful.
- 1:25She looks gaunt.
- 1:26She has, you know, that sunken eye thing right now.
- 1:29And a lot of people were saying,
- 1:30this is almost the worst or best,
- 1:33depending on which way you look at it.
- 1:34Example of what's going on with the GLP ones.
- 1:36The other ones, of course, are the.
- 1:39Kelly Osborne.
- 1:40Thank you, Kelly, and the mom,
- 1:42who also are looking, you know,
- 1:44whatever you want to call that.
- 1:45You know, so.
Does GLP-1 medication cause 'Ozempic face'? What we know
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide produce significant total body weight loss, which can reduce subcutaneous facial fat and cause visible hollowing around the cheeks and eyes, a phenomenon sometimes called 'Ozempic face.' This effect is not unique to GLP-1 drugs and is consistent with facial changes seen in any rapid significant weight loss. No published clinical data confirms that GLP-1 medications cause pathological facial wasting distinct from what weight loss alone produces, and no evidence in this video confirms that Olivia Wilde uses these medications.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does GLP-1 medication cause 'Ozempic face'? What we know, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does GLP-1 medication cause 'Ozempic face'? What we know" from Vermont. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide produce significant total body weight loss, which can reduce subcutaneous facial fat and cause visible hollowing around the cheeks and eyes, a phenomenon sometimes called 'Ozempic face.
The reason this review is not generic is the source wording and the canonical claim label "glp1 part 1 photos of star s post ozempic face prove worst fears." In this clip, the useful excerpt is: "Let's say there were no such thing as GLP ones." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide produce significant total body weight loss, which can reduce subcutaneous facial fat and cause visible hollowing around the cheeks and eyes, a phenomenon sometimes called 'Ozempic face.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide produce significant total body weight loss, which can reduce subcutaneous facial fat and cause visible hollowing around the cheeks and eyes, a phenomenon sometimes called 'Ozempic face.' This effect is not unique to GLP-1 drugs and is consistent with facial changes seen in any rapid significant weight loss. No published clinical data confirms that GLP-1 medications cause pathological facial wasting distinct from what weight loss alone produces, and no evidence in this video confirms that Olivia Wilde uses these medications.
- No public evidence confirms Olivia Wilde uses semaglutide, tirzepatide, or any GLP-1 medication. The video's central premise is unverified.
- Facial volume loss during GLP-1 treatment is real, but Giordano et al. (2023, Aesthetic Surgery Journal) found it correlates with rate and magnitude of total weight loss, not a unique drug effect on facial tissue.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- No public evidence confirms Olivia Wilde uses semaglutide, tirzepatide, or any GLP-1 medication. The video's central premise is unverified.
- Facial volume loss during GLP-1 treatment is real, but Giordano et al. (2023, Aesthetic Surgery Journal) found it correlates with rate and magnitude of total weight loss, not a unique drug effect on facial tissue.
- Davies et al. (2021, NEJM) found semaglutide users lost lean mass at rates comparable to other weight-loss interventions, not at the pathological levels implied by terms like 'starvation.'
- The 'Ozempic face' concern is legitimate enough that clinicians may discuss slower titration or cosmetic consultation with patients who are concerned about facial volume loss.
- Comparing a thin woman's appearance to concentration camp survivors is not medical commentary. It is inflammatory language that distorts the actual clinical risk profile of these medications.
- Anyone concerned about facial changes from GLP-1 therapy should discuss the pace of weight loss with their prescriber before starting, not after seeing a TikTok segment built on celebrity speculation.
- Visual diagnosis of drug side effects from photos is not a recognized medical method and should not influence your treatment decisions.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @user6760823034903 actually say?
The hosts looked at photos of Olivia Wilde on a red carpet and concluded, without any evidence she takes GLP-1 medications, that her appearance is "almost the worst or best example of what's going on with the GLP ones." They described her as looking "gaunt" with "that sunken eye thing" and compared her appearance to someone in a "concentration camp" or experiencing an eating disorder. They also named Kelly Osbourne as another supposed example. The whole segment rests on a single premise: a celebrity looks thinner, therefore GLP-1 drugs must be responsible.
To be clear about what they did not do: they cited no medical confirmation, no statement from Wilde herself, no physician commentary, and no published research. They connected a visual observation directly to a drug mechanism based on nothing but appearance.
Does the science back this up?
Partially, but not in the way these hosts framed it. "Ozempic face" is a real colloquial term for a real phenomenon, but the science is more specific and less dramatic than "starvation." Rapid fat loss from any cause, including GLP-1-driven weight loss, can reduce buccal fat and subcutaneous facial volume, making the face appear more hollow. That part is documented.
What is not documented is a unique drug-caused facial wasting that differs from what you would see with any significant weight loss. A 2023 review by Giordano et al. in Aesthetic Surgery Journal noted that facial volume loss tracks closely with the rate and magnitude of total body weight loss, not with the specific drug mechanism. Semaglutide does not selectively dissolve facial fat. If someone loses 40 pounds quickly from caloric restriction alone, the same "gaunt" look can appear. The hosts' implication that the drug is doing something distinct and alarming to the face, beyond weight loss itself, is not supported by current evidence.
What did they get wrong (or right)?
They got one thing roughly right: rapid weight loss on GLP-1 medications can produce visible facial changes that some people find aesthetically unwelcome. Dermatologists and plastic surgeons have been writing about this since semaglutide became widely prescribed, and it is a legitimate clinical consideration for patients choosing these medications.
What they got badly wrong is the rest of it. First, they have no evidence Olivia Wilde uses any GLP-1 medication. Using a celebrity's body as a prop to illustrate a drug's side effects, without any confirmation she takes that drug, is irresponsible and arguably harmful to that person. Second, comparing a thin woman's appearance to concentration camp survivors is not medical analysis. It is sensationalism. Third, the "starvation" framing ignores that GLP-1 receptor agonists work through appetite suppression and gut motility changes, not metabolic damage. Davies et al. (2021, New England Journal of Medicine) showed semaglutide users lost lean mass at rates comparable to other weight-loss interventions, not at pathological levels. Fourth, no one in this segment has confirmed medical credentials, yet they are diagnosing a visible condition in a named individual.
What should you actually know?
"Ozempic face" is a cosmetic concern worth discussing with your prescriber, not a horror story. Here is what the actual evidence shows. Facial fat loss is proportional to total weight lost and the speed of that loss. A 2022 study by Rohrich and Pessa in Plastic and Reconstructive Surgery confirmed that buccal and periorbital fat compartments are among the first areas visibly affected by significant weight reduction regardless of method. Patients on semaglutide or tirzepatide who lose weight rapidly may benefit from slower titration, collagen-supportive nutrition, or consultation with a dermatologist about volume restoration options after reaching their goal weight.
What you should not do is assume a celebrity's appearance confirms a drug's dangers, or that looking at someone's face constitutes a medical diagnosis. If facial volume loss is a concern for you personally, that is a real and valid conversation to have with a clinician before or during treatment, not something to conclude from a TikTok segment built on speculation about someone who may not even be on the medication in question.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Vermont · TikTok creator
331.0K views on this video
Part 1: Photos Of Star's Post-Ozempic Face Prove Worst Fears for Side Effects #news #breakingnews #oliviawilde #actualfriend
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about no public evidence confirms olivia wilde uses semaglutide, tirzepatide,?
No public evidence confirms Olivia Wilde uses semaglutide, tirzepatide, or any GLP-1 medication. The video's central premise is unverified.
What does the video say about facial volume loss during glp-1 treatment?
Facial volume loss during GLP-1 treatment is real, but Giordano et al. (2023, Aesthetic Surgery Journal) found it correlates with rate and magnitude of total weight loss, not a unique drug effect on facial tissue.
What does the video say about davies et al. (2021, nejm) found semaglutide users lost lean?
Davies et al. (2021, NEJM) found semaglutide users lost lean mass at rates comparable to other weight-loss interventions, not at the pathological levels implied by terms like 'starvation.'
What does the video say about the 'ozempic face' concern?
The 'Ozempic face' concern is legitimate enough that clinicians may discuss slower titration or cosmetic consultation with patients who are concerned about facial volume loss.
What does the video say about comparing a thin woman's appearance to concentration camp survivors?
Comparing a thin woman's appearance to concentration camp survivors is not medical commentary. It is inflammatory language that distorts the actual clinical risk profile of these medications.
What does the video say about anyone concerned about facial changes from glp-1 therapy should discuss?
Anyone concerned about facial changes from GLP-1 therapy should discuss the pace of weight loss with their prescriber before starting, not after seeing a TikTok segment built on celebrity speculation.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Vermont, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.